1. Introduction Cardiac tumors are classified as primary or metastatic tumors. Metastatic cardiac tumors are the most common type and are approximately 30 times more common than primary cardiac tumors (1). Benign primary cardiac tumors account for approximately 80% of all cases, with myxomas being the most common, followed by lipomas, papillary fibroelastomas, and rhabdomyomas. Malignant primary cardiac tumors are rare and predominantly comprise various forms of sarcoma (2).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chiara Lestuzzi
Case report: Cardiac intimal sarcoma in a young child
Keywords: Intimal sarcoma, Cardiac, Child, MDM2, right ventricle (RV) © 2023 Verbeek, Sciot, Debiec-Rychter, Labarque, Meyns and Cools. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
Editorial: Cardiovascular sequelae of chemotherapy and radiotherapy in cancer survivors: current evidence and perspectives
Editorial on the Research Topic Cardiovascular sequelae of chemotherapy and radiotherapy in cancer survivors: current evidence and perspectives Cardiovascular diseases and cancer are the two leading causes of morbidity and premature death worldwide (1, 2). In the past decade, the survival of cancer patients has impressively increased, mainly through screening modalities improvement and development of novel anticancer drugs (1, 2).
Impact of health insurance and socioeconomic status in the outcome of cancer and cardiac diseases
In this issue of the IJC, an interesting paper analyzes the outcome of 123 cases of an extremely rare pathology: Cardiac (c) Diffuse Large B-Cell Lymphoma (DLBCL) [ ]. The aim of the study was to verify if the outcome of this subgroup of DLBCL had improved after 2006, the year the Food and Drug Administration approved Rituximab, a monoclonal antibody (Mab) used for DLBCL therapy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chiara
Contact Chiara, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack